Natural antimicrobials subtilosin and lauramide arginine ethyl ester synergize with conventional antibiotics clindamycin and metronidazole against biofilms of Gardnerella vaginalis but not against biofilms of healthy vaginal lactobacilli

Pathogens and Disease

Volumn 73, Issue 5, 2015, Pages

  Algburi, Ammar ^a,b   Volski, Anna ^a   Chikindas, Michael L ^c  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF DIYALA   (Iraq)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Antimicrobial synergy; Biofilm; Gardnerella vaginalis; Natural antimicrobials

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN PHOSPHATE; LAURAMIDE ARGININE ETHYL ESTER; METRONIDAZOLE; NATURAL PRODUCT; SUBTILOSIN; UNCLASSIFIED DRUG; ARGININE; ARGININE ETHYL ESTER; BACTERIOCIN; CLINDAMYCIN; CYCLOPEPTIDE; ETHANOLAMINE DERIVATIVE; SBOA PROTEIN, BACILLUS SUBTILIS;

ARTICLE; ASSAY; BACTERICIDAL ACTIVITY; BIOFILM; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GARDNERELLA INFECTION; HUMAN; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS VAGINALIS; MINIMUM BACTERICIDAL CONCENTRATION; MOBILUNCUS CURTISII; NONHUMAN; PEPTOSTREPTOCOCCUS ANAEROBIUS; PLANKTON; PREVOTELLA BIVIA; PRIORITY JOURNAL; VAGINITIS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GARDNERELLA VAGINALIS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; VAGINA;

ANTI-BACTERIAL AGENTS; ARGININE; BACTERIOCINS; BIOFILMS; CLINDAMYCIN; DRUG SYNERGISM; ETHANOLAMINES; FEMALE; GARDNERELLA VAGINALIS; HUMANS; LACTOBACILLUS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; VAGINA;

EID: 84954611910     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftv018     Document Type: Article

References (95)

1. Al Kassaa I, Hamze M, Hober D, et al. Identification of vaginal lactobacilli with potential probiotic properties isolated from women in North Lebanon. Microb Ecol 2014;67: 722-34.
2. Anukam KC, Reid G. Effects of metronidazole on growth of Gardnerella vaginalis ATCC 14018, probiotic Lactobacillus rhamnosus GR-1 and vaginal isolate Lactobacillus plantarum KCA. Microb Ecol Health D 2008;20:48-52.
3. Austin MN, Meyn LA, Hillier SL. Susceptibility of vaginal bacteria to metronidazole and tinidazole. Anaerobe 2006;12:227-30.
4. Baker DD, Chu M, Oza U, et al. The value of natural products to future pharmaceutical discovery. Nat Prod Rep 2007;24:1225-44.
5. Bannatyne RM, Smith AM. Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis. Sex Transm Infect 1998;74:455-6.
6. Barbieri RL. Successful treatment of chronic vaginitis. OBG Manag 2013;25:10-2.
7. Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004;191:1124-9.
8. Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002;511:133-44.
9. Bonnaud M, Weiss J, McClements DJ. Interaction of a food-grade cationic surfactant (lauric arginate) with food-grade biopolymers (pectin, carrageenan, xanthan, alginate, dextran, and chitosan). J Agr Food Chem 2010;58:9770-7.
10. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478-86.
11. Braga PC, dal Sasso M, CuliciM, et al. Inhibitory activity of thymol on native and mature Gardnerella vaginalis biofilms: in vitro study. Arzneimittelforschung 2010;60:675-81.
12. Brocklehurst P, Gordon A, Heatley E, et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Db Syst Rev 2013, 10.1002/14651858.
13. Cavera V, Volsky A, Chikindas ML. The natural antimicrobial subtilosin A synergizes with lauramide arginine ethyl ester (LAE), γ-poly-L-lysine, clindamycin phosphate and metronidazole, against the vaginal pathogen Gardnerella vaginalis. Probiotics. Antimicro Proteins 2015; DOI: 10.1007/s12602-014-9183-1.
14. Chambers HF. Bactericidal vs. bacteriostatic antibiotic therapy: a clinical mini-review. Clin Updat Infect Dis 2003;6:1-4.
15. Chen DG, Pounds JG. A nonlinear isobologram model with boxcox transformation to both sides for chemical mixtures. Environ Health Persp 1998;106:1367-71.
16. Choi H, Lee DG. Antimicrobial peptide pleurocidin synergizes with antibiotics through hydroxyl radical formation and membrane damage, and exerts anti-bioffilm activity. Biochim Biophys Acta 2012a;1820:1831-8.
17. Choi H, Lee DG. Synergistic effect of antimicrobial peptide arenicin-1 in combination with antibiotics against pathogenic bacteria. Res Microbiol 2012b;163:479-86.
18. Church DL, Bryant RD, Sim V, et al. Metronidazole susceptibility and the presence of hydrogenase in pathogenic bacteria. Anaerobe 1996;2:147-53.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility test. Twentieth Informational Supplement M100-S20. Wayne, PA, USA, 2010.
20. Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012;9:1-9.
21. Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med 1997;73:267-70.
22. Coppola R, Succi M, Tremonte P, et al. Antibiotic susceptibility of Lactobacillus rhamnosus strains isolated from Parmigiano Reggiano cheese. Lait 2005;85:193-204.
23. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005;3:777-88.
24. Cotton LA, Graham RJ, Lee RJ. The role of alginate in P. aeruginosa PAO1 biofilm structural resistance to gentamicin and ciprofloxacin. J Exp Microbiol Immunol 2009;13:58-62.
25. Danne C, Dramsi S. Pili of Gram-positive bacteria: roles in host colonization. Res Microbiol 2012;163:645-58.
26. De Vuyst L, de Vin F, Vaningelgem F, et al. Recent developments in the biosynthesis and applications of heteropolysaccharides from lactic acid bacteria. Int Dairy J 2001;11:687-707.
27. Di Luca M, Maccari G, Nifosi R. Treatment of microbial biofilms in the post-antibiotic era: prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools. Pathog Dis 2014;70:257-70.
28. Dover SE, Aroutcheva AA, Faro S, et al. Natural antimicrobials and their role in vaginal health: a short review. Int J Probiotics Prebiotics 2008;3:219-30.
29. Draper LA, Cotter PD, Hill C, et al. The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. BMC Microbiol 2013; 13:212.
30. Forde BM, Neville BA, O'Donnell MM, et al. Genome sequences and comparative genomics of two Lactobacillus ruminis strains from the bovine and human intestinal tracts. Microb Cell Fact 2011;10:S13.
31. Forsum U, Holst E, Larsson PG, et al. Bacterial vaginosis, amicrobiological and immunological enigma. Acta Pathol Micro Im Sc 2005;113 81-90.
32. Golowczyc MA, Mobili P, Garrote GL, et al. Protective action of Lactobacillus kefir carrying S-layer protein against Salmonella enterica serovar Enteritidis. Int J Food Microbiol 2007;118: 264-73.
33. Graham S, Howes C, Dusmuir R, et al. Vertebral osteomyelitis and discitis due to Gardnerella vaginalis. J Med Microbiol 2009;58:1382-4.
34. Hamilton HM, Heersink J. How to optimize the drop plate method for enumerating bacteria. J Microbiol Meth 2001;44:121-9.
35. Henriques AF, Martinez-de-Oliveira J, Cerca N. Doctor's perception on bacterial vaginosis in Portugal: prevalence, diagnostic methods and choice of treatment. Sex Transm Infect 2012;88:421.
36. Higaki S, Kitagawa T, Kagoura M, et al. Characterization of Peptostreptococcus species in skin infections. J Int Med Res 2000;28:143-7.
37. Hillier S, Krohn MA, Watts DH, et al. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol 1990;76:407-13.
38. Hubrechts JM, Vanhoof RL, Daems A, et al. Susceptibility of Gardnerella vaginalis to thiamphenicol: clinical experience with nonspecific vaginitis. Sex Transm Dis 1984;11:456-9.
39. Hymes SR, Randis TM, Sun TY, et al. DNase inhibits Gardnerella vaginalis bioffilms in vitro and In vivo. J Infect Dis 2013;207:1491-7.
40. Infante R, Garciá Domińguez J, Erra P, et al. Surface active molecules: preparation and properties of long chain Na-acyl-L-a-amino-x-guanidine alkyl acid derivatives. Int J Cosmetic Sci 1984;6:275-82.
41. IsmailWH, Razak FA, AbdulRahim ZH. The role of sucrose in the development of oral biofilm in a simulated mouth system. Online J Biol Sci 2006;6:62-6.
42. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: Review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999;28:57-65.
43. John ES, Mares D, Spear GT. Bacterial vaginosis and host immunity. Curr HIV/AIDS Rep 2007;4:22-8.
44. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol 2009;9:1-9.
45. Kandimalla KK, Borden E, Omtri RS, et al. Ability of chitosan gels to disrupt bacterial bioffilms and their applications in the treatment of bacterial vaginosis. J Pharm Sci 2013;102: 2096-101.
46. Kandler O, Weiss N. Genus Lactobacillus. In: Sneath PHA, Mair NS, Sharpe MS, et al., (eds). Bergey's Manual of Systematic Bacteriology, Baltimore, MD: Williams & Wilkins, 1986, 1063-5.
47. Kaur S, Sharma P. Invitro synergistic antimicrobial activity of bacteriocin of vaginal lactobacilli and antibiotics against Pseudomonas aeruginosa. Int J Biotech Bioeng Res 2013;4:573-4.
48. Klare I, Konstabel C, Werner G, et al. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemoth 2007;59:900-12.
49. Könönen E, Bryk A, Niemi P, et al. Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources. Antimicrob Agents Ch 2007;51:2205-7.
50. Koss CA, Barasc DC, Laned SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Ch 2012;56:94800-5.
51. Kubota H, Senda S, Tokuda H, et al. Stress resistance of biofilm and planktonic Lactobacillus plantarum subsp. plantarum JCM 1149. Food Microbiol 2009;26:592-7.
52. Larsson PG, Forsum U. Bacterial vaginosis-a disturbed bacterial flora and treatment enigma, Acta Pathol Micro Im Sc 2005;113:305-16.
53. Lebeer S, Claes I, Tytgat HLP, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microb 2012;78:185-93.
54. Lebeer S, de Keersmaecker SCJ, Verhoeven TLA, et al. Functional analysis of luxS in the probiotic strain Lactobacillus rhamnosus GG reveals a central metabolic role important for growth and biofilm formation. J Bacteriol 2007;189:860-71.
55. Lortal S, van Heijenoort J, Gruber K, et al. S-layer of Lactobacillus helveticus ATCC 12046: isolation, chemical characterization and reformation after extraction with lithium chloride. J Gen Microbiol 1992;138:611-8.
56. Lourenço A, Coenye T, Goeres DM, et al. Minimum information about a biofilm experiment (MIABiE): standards for reporting experiments and data on sessile microbial communities living at interfaces. Pathog Dis 2014;70:250-6.
57. Machado A, Jefferson KK, Cerca N. Interactions between Lactobacillus crispatus and bacterial vaginosis BV-associated bacterial species in initial attachment and biofilm formation. Int J Mol Sci 2013;14:12004-12.
58. Martín R, Soberón N, Vaneechoutte M, et al. Characterization of indigenous vaginal lactobacilli from healthy women as probiotic candidates. Int Microbiol 2008;11:261-6.
59. Mascarenhas REM, Machado MSC, da Costa e Silva BFB, et al. Prevalence and risk factors for bacterial vaginosis and other vulvovaginitis in a population of sexually active adolescents from Salvador, Bahia, Brazil. Infec Dis Obstet Gynecol 2012;2012:8. DOI: 10.1155/2012/378640.
60. Michelle C, Meltzer BS, MT(ASCP), et al. Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis 2008;35:611-3.
61. Mikamo H, Sato Y, Hayasaki Y, et al. Intravaginal bacterial flora in patients with uterine cervical cancer. High incidence of detection of Gardnerella vaginalis. J Infect Chemother 1999;5: 82-5.
62. Millsap KW, Reid G, van der Mei HC, et al. Adhesion of Lactobacillus species in urine and phosphate buffer to silicone rubber and glass under flow. Biomaterials 1997;18:87-91.
63. Minahk CJ, Dupuy F, Morero RD. Enhancement of antibiotic activity by sublethal concentrations of enterocin CRL35. J Antimicrob Chemoth 2004;53:240-6.
64. Naghmouchi K, Belguesmia Y, Baah J, et al. Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Res Microbiol 2011;162:99-107.
65. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297-301.
66. Ocãna VS, Nader-Macias ME. Adhesion ability of Lactobacillus to vaginal epithelial cells. Methods Mol Biol 2004;268:441-5.
67. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Db Syst Rev 2009, DOI: 10.1002/14651858.CD006055.
68. Pathak M, Turner M, Palmer C, et al. Evaluation of polycaprolactone matrices for the intravaginal delivery of metronidazole in the treatment of bacterial vaginosis. J Biomater Appl 2014;29:354-63.
69. Patterson JL, Stull-Lane A, Girerd PH, et al. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial vaginosis-associated anaerobes. Microbiology 2010;156:392-9.
70. Qu Y, Daley AJ, Istivan TS, et al. Densely adherent growth mode, rather than extracellular polymer substance matrix build-up ability, contributes to high resistance of Staphylococcus epidermidis biofilms to antibiotics. J Antimicrob Chemoth 2010;65:1405-11.
71. Rodriguez E, Seguer J, Rocabayera X, et al. Cellular effects of monohydrochloride of l-arginine, N-lauroyl ethylester (LAE) on exposure to Salmonella typhimurium and Staphylococcus aureus. J Appl Microbiol 2004;96:903-12.
72. Saunders S, Bocking A, Challis J, et al. Effect of Lactobacillus challenge on Gardnerella vaginalis biofilms. Colloid Surface B 2007;55:138-42.
73. Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011;204:1-6.
74. Schwebke JR, Lawing LF. Prevalence of Mobiluncus spp among women with and without bacterial vaginosis as detected by polymerase chain reaction. Sex Transm Dis 2001;28:195-9.
75. Scott TG, Smyth CJ. Hemagglutination and tissue culture adhesion of Gardnerella vaginalis. J Gen Microbiol 1987;133:1999-2005.
76. Shemesh M, Tam A, Steinberg D. Expression of biofilmassociated genes of Streptococcus mutans in response to glucose and sucrose. J Med Microbiol 2007;56:1528-35.
77. Simoes JA, Aroutcheva AA, Shott S, et al. Effect of metronidazole on the growth of vaginal lactobacilli in vitro. Infect Dis Obstet Gynecol 2001;9:41-50.
78. Sobel JD. Bacterial vaginosis. Annu Rev Med 2000;1:349-56.
79. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Ch 1987;31:249-52.
80. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-38.
81. Stranz MH, Bradley WE. Metronidazole (flagyl IV, searle). Drug Intel Clin Phar 1981;15:838-46.
82. Sturme MHJ, Nakayama J, Molenaar D, et al. An agr-like twocomponent regulatory system in Lactobacillus plantarum is involved in production of novel cyclic peptide and regulation of adherence. J Bacteriol 2005;187:5224-35.
83. Sutyak KE, Wirawan RE, Aroutcheva AA, et al. Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. J Appl Microbiol 2008;104:1067-74.
84. Sutyak Noll K, Prichard MN, Khaykin A, et al. The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate and γ-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli. Antimicrob Agents Ch 2012;56:1756-61.
85. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005;106: 1013-23.
86. Swidsinski A, MendlingW, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008;198:1-6.
87. Syed TS, Braverman PK. Vaginitis in adolescents. Adolesc Med 2001;15:235-51.
88. Tenuta MA, Filho APR, del Bel Cury AA, et al. Effect of sucrose on the selection of mutans streptococci and lactobacilli in dental biofilm formed in situ. Caries Res 2006;40:546-9.
89. Thennarasua S, Leea DK, Poona A, et al. Membrane permeabilization, orientation, and antimicrobial mechanism of subtilosin A. Chem Phys Lipids 2005;137:38-51
90. Theron MM, Janse van Rensburg MN, Chalkley LJ. Nitroimidazole resistance genes (nimB) in anaerobic gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemoth 2004;54:240-2.
91. Turovskiy Y, Cheryian T, Algburi A, et al. Susceptibility of Gardnerella vaginalis biofilms to natural antimicrobials subtilosin, γ-poly-L-lysine, and lauramide arginine ethyl ester. Infect Dis Obstet Gynecol 2012;2012:8. DOI: 10.1155/2012/284762.
92. Turovskiy Y, Chikindas ML. Zinc lactate and sapindin act synergistically with lactocin 160 against Gardnerella vaginalis. Probiotics Antimicrob Proteins 2011;3:144-9.
93. Woojin P, Jae-Sook R, Jaesook R. Lactobacillus acidophilus contributes to a healthy environment for vaginal epithelial cells. Korean J Parasitol 2011;49:295-8.
94. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2010;59(RR12):1-110.
95. Yang SC, Lin CH, Sung CT, et al. Antibacterial activities of bacteriocins: application in foods and pharmaceuticals. Front Microbiol 2014;5:241, DOI: 10.3389/fmicb.2014.00241.